학술논문
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Document Type
Article
Author
Kohsaka, Shun; Lam, Carolyn S P; Kim, Dae Jung; Cavender, Matthew A; Norhammar, Anna; Jørgensen, Marit E; Birkeland, Kåre I; Holl, Reinhard W; Franch-Nadal, Josep; Tangri, Navdeep; Shaw, Jonathan E; Ilomäki, Jenni; Karasik, Avraham; Goh, Su-Yen; Chiang, Chern-En; Thuresson, Marcus; Chen, Hungta; Wittbrodt, Eric; Bodegård, Johan; Surmont, Filip; Fenici, Peter; Kosiborod, Mikhail; Kosiborod, Mikhail; Cavender, Matthew A; Wilding, John P; Khunti, Kamlesh; Norhammar, Anna; Birkeland, Kåre; Jørgensen, Marit Eika; Holl, Reinhard W.; Lam, Carolyn SP; Gulseth, Hanne Løvdal; Carstensen, Bendix; Bollow, Esther; Franch-Nadal, Josep; García Rodríguez, Luis Alberto; Karasik, Avraham; Tangri, Navdeep; Kohsaka, Shun; Kim, Dae Jung; Shaw, Jonathan; Arnold, Suzanne; Goh, Su-Yen; Fenici, Peter; Bodegård, Johan; Chen, Hungta; Surmont, Filip; Blak, Betina T.; Wittbrodt, Eric T.; Saathoff, Matthias; Noguchi, Yusuke; Tan, Donna; Williams, Maro; Lee, Hye Won; Greenbloom, Maya; Kaidanovich-Beilin, Oksana; Yeo, Khung Keong; Bee, Yong Mong; Khoo, Joan; Koong, Agnes; Lau, Yee How; Gao, Fei; Tan, Wee Boon; Kadir, Hanis Abdul; Ha, Kyoung Hwa; Lee, Jinhee; Chodick, Gabriel; Melzer-Cohen, Cheli; Whitlock, Reid; Cea-Soriano, Lucia; Cantero, Oscar Fernándex; Menzin, Jordan A.; Guthrie, Matthew; Ilomaki, Jennie; Magliano, Dianna
Source
The Lancet Diabetes & Endocrinology; July 2020, Vol. 8 Issue: 7 p606-615, 10p
Subject
Language
ISSN
22138587; 22138595
Abstract
Cardiovascular outcome trials have shown cardiovascular benefit with sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with type 2 diabetes, whereas dipeptidyl peptidase-4 (DPP-4) inhibitors have not shown an effect. We aimed to address knowledge gaps regarding the comparative effectiveness of SGLT2 inhibitor use in clinical practice (with DPP-4 inhibitor use as an active comparator) across a range of cardiovascular risks and in diverse geographical settings.